Acute migraine? NICE recommends Pfizer’s rimegepant as potential option
The National Institute for Health and Care Excellence (NICE) has released conclusive draft guidance, suggesting Pfizer's Vydura (rimegepant) as a choice for treating acute...
Engage with Experts: Connect with industry leaders, renowned pharmacists, and forward-thinking researchers through exclusive live Q&A sessions and engaging discussions. Tap into their wisdom, ask burning questions, and gain invaluable insights to fuel your passion for pharmacy
Copyright © 2023 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc